eisai integrated report 2020

Eisai Rated "A", the highest rating in the CDP Climate Change Report 2019. The organization and its reporting practices, Entities included in the organizations sustainability reporting, Reporting period, frequency and contact point, Activities, value chain and other business relationships, Nomination and selection of the highest governance body, Role of the highest governance body in overseeing the management of impacts, Delegation of responsibility for managing impacts, Role of the highest governance body in sustainability reporting, Collective knowledge of the highest governance body, Evaluation of the performance of the highest governance body, Statement on sustainable development strategy, Mechanisms for seeking advice and raising concerns, Direct economic value generated and distributed, Financial implications and other risks and opportunities due to climate change, Defined benefit plan obligations and other retirement plans, Financial assistance received from government, Ratios of standard entry level wage by gender compared to local minimum wage, Proportion of senior management hired from the local community, Infrastructure investments and services supported, Proportion of spending on local suppliers, Operations assessed for risks related to corruption, Communication and training about anti-corruption policies and procedures, Confirmed incidents of corruption and actions taken, Legal actions for anti-competitive behavior, anti-trust, and monopoly practices, Tax governance, control, and risk management, Stakeholder engagement and management of concerns related to tax, Reclaimed products and their packaging materials, Energy consumption within the organization, Energy consumption outside of the organization, Reductions in energy requirements of products and services, Interactions with water as a shared resource, Management of water discharge-related impacts, Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas, Significant impacts of activities, products, and services on biodiversity, IUCN Red List species and national conservation list species with habitats in areas affected by operations, Emissions of ozone-depleting substances (ODS), Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions, Waste generation and significant waste-related impacts, Management of significant waste-related impacts, Non-compliance with environmental laws and regulations, New suppliers that were screened using environmental criteria, Negative environmental impacts in the supply chain and actions taken, Benefits provided to full-time employees that are not provided to temporary or part-time employees, Minimum notice periods regarding operational changes, Occupational health and safety management system, Hazard identification, risk assessment, and incident investigation, Worker participation, consultation, and communication on occupational health and safety, Worker training on occupational health and safety, Prevention and mitigation of occupational health and safety impacts directly linked by business relationships, Workers covered by an occupational health and safety management system, Average hours of training per year per employee, Programs for upgrading employee skills and transition assistance programs, Percentage of employees receiving regular performance and career development reviews, Diversity of governance bodies and employees, Ratio of basic salary and remuneration of women to men, Incidents of discrimination and corrective actions taken, Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk, Operations and suppliers at significant risk for incidents of child labor, Operations and suppliers at significant risk for incidents of forced or compulsory labor, Security personnel trained in human rights policies or procedures, Incidents of violations involving rights of indigenous peoples, Operations that have been subject to human rights reviews or impact assessments, Employee training on human rights policies or procedures, Significant investment agreements and contracts that include human rights clauses or that underwent human rights screening, Operations with local community engagement, impact assessments, and development programs, Operations with significant actual and potential negative impacts on local communities, New suppliers that were screened using social criteria, Negative social impacts in the supply chain and actions taken, Assessment of the health and safety impacts of product and service categories, Incidents of non-compliance concerning the health and safety impacts of products and services, Requirements for product and service information and labeling, Incidents of non-compliance concerning product and service information and labeling, Incidents of non-compliance concerning marketing communications, Substantiated complaints concerning breaches of customer privacy and losses of customer data, Non-compliance with laws and regulations in the social and economic area. Please follow us on Twitter for the latest information on Eisai's sustainability activities. 2017. Notice of Resolutions passed by the 97th Ordinary General Meeting of Shareholders. WOODCLIFF LAKE, N.J., Aug. 11, 2020 /PRNewswire/ -- Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., . Post Author: Post published: 21st May 2022 Post Category: junior architectural designer salary Post Comments: coachella festival demographics coachella festival demographics Download all PDFs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative . It operates through the Pharmaceutical By using this site, you agree to our use of cookies. (For our 2021 Integrated Report, please click here .) Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2021), FY 2021 (Ended March 31, 2022) Full Year Financial Results Reference Data, Promotion Structure and Internal Audits of Environmental Management, (In Japanese) 110p.50-, (In Japanese)110p.50-, (In Japanese)110p.53-, (In Japanese)110p.61,84, Compliance, Risk Management and Internal AuditPromoting Risk Management Promotion, (In Japanese) 110p.58-61, (In Japanese) 110p.55-56, (In Japanese) 110p.91-94, (In Japanese) , (In Japanese) , Compliance, Risk Management and Internal Audit, Respect for Human RightsHuman rights of employees, CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022) p.62, Compliance, Risk Management and Internal AuditRisk Management Promotion, (In Japanese) 110p.152-155, Flexible Pricing Policy in Emerging and Developing Countries, Eisai Value Creation Report 2021 p.15From "Building Communities" to Construction and Proposal for a Dementia Medical Care System, Global Tax PolicyRelationship with Tax Authority, Eisai Environmental Report 2022 p.3, 5, 10, 12, Eisai Environmental Report 2022 p.4, 9, 11, Eisai Environmental Report 2022 p.5, 17-19, Eisai Environmental Report 2022 p.5, 9-12, Eisai Environmental Report 2022 p.5, 911, Eisai Environmental Report 2022 p.14, 15, 17-19, Eisai Environmental Report 2022 p.5, 13-15, Eisai Environmental Report 2022 p.7, 8, 13-15, Eisai Environmental Report 2022 p.5, 13, 18, 19, Eisai Value Creation Report 2022 p.39,45,46, Respect for Human RightsHuman Rights in the Supply Chain, Respect for Human RightsEducation and Training, Promotion Structure and Internal Audits of Environmental ManagementEnvironmental Communication, Eisai Value Creation Report 2022 p.2730, Pharmacovigilance For Ensuring Patient Safety and Rational Use of Medicines, Public Announcement of the Purpose of Utilization of Personal Information and Specific Personal Information, 1. Initiatives for Improving Access to Medicines. This website uses cookies to enhance your browsing experience. LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA. Our employees make, sell and distribute the world's most loved drinks brands, serving a consumer population . Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Wednesday, November 30, 2022 09:50 a.m.- (JST). Hong Kong Life Sciences Society (HKLSS) is an organisation established in 2018 aiming to build a dynamic life sciences ecosystem in Hong Kong. 'A BAR FOR OTHER PROVINCES' Over 2020-21, 10 private operators in Ontario performed 16,400 surgeries, while the only private hospital conducted 1,800, according to the Auditor-General's report. DEP encourages the public to provide constructive comments during this period. Published. We are delivering a smoke-free future. 2. Use a + to require a term in results and - to exclude terms. Freelance services: Custom-Made, Made-to-Order and Ready-to-Wear clothing. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia . If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. Integrated Reportsformerly Annual Reports 2020. Analyst & Investor Briefing on 09.09.2022. Hong Kong Life Sciences Society. (2) The Company's mission is the enhancement of patient satisfaction. Eisai Laboratorios, S. de R. L. de C.V., located in Mexico, is a subsidiary of Eisai Inc. a company based in the United States. Integrated Report 2020. (1) The Company's Corporate Philosophy is to give first thought to patients and their families, and increase the benefits that health care provides them. Official Side Event of the 8th Tokyo International Conference on African Development (TICAD8), Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Media/Investor Conference: Eisais Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimers Disease (Video), Recent hhc Activities Promoting Global Knowledge Exchange through 'hhc Initiative 2022', About Eisai Corporate Governance Report Notice, Wednesday, November 30, 2022 09:50 a.m.- (JST)Full Findings of Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) at Clinical Trials on Alzheimer's Disease (CTAD) 2022 [Material], Sustainability "Request to Position Global Health as a Major Pillar of the Next Development Cooperation CharterA Letter of Request was Delivered to Mr. Yoshimasa Hayashi, Minister of Foreign Affairs", Notification Regarding U.S. Research and Development Subsidiary, Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimers Disease, EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY, Eisai formulates the action plan Diversity & Inclusion 2021, Second Quarter Financial Results for Fiscal Year Ending March 31, 2023, Our Response to the Novel Coronavirus Infection, #ThisIsMBC Campaign for Patients with Metastatic Breast Cancer, Number of countries supplied with lymphatic filariasis treatment Owned . Through knowledge exchange, collaboration, and engagement, HKLSS aims to attract, cultivate, and retain talent in Hong Kong's life sciences and biotechnology sectors. January 7, 2023. Copyright Eisai Co., Ltd. All Rights Reserved. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. April 2019 - March 2020 Files. Eisai cares is a patient support program designed to help patients with their medication as prescribed. Jun 2020 - Jan 20221 year 8 months. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. GRI 405: Diversity and Equal Opportunity 2016. Diversity of governance bodies and employees. In order to realize Eisais purpose the human health care (hhc) concept, it is necessary to implement corporate policies based on a long-term perspective under a well-cultivated governance structure. Stand alone document; Differentiation Level This COP qualifies for the Global Compact Active level EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers DiseaseSubmission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial, Eisais Commitment to Scientific Evidence and Patient Safety, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINEMAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers DiseaseAccelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials, YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAIS SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS, ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA, Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging, EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS, EISAI TERMINATES SPONSORED AMERICAN DEPOSITARY RECEIPT PROGRAM, EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES, EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE AT CLINICAL TRIALS ON ALZHEIMERS DISEASE (CTAD) CONFERENCE, ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE, (REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research, EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE, METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS, EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON IN ASIA TO DKSH, EISAI'S SALES SUBSIDIARY COLLABORATES WITH THAI LIFE INSURANCE TO SUPPORT ACCESS TO TREATMENTS FOR DEMENTIA, INCLUDING ALZHEIMERS DISEASE, IN THAILAND, EISAI SATISFIES ALL-CASE STUDY REQUIREMENT FOR ANTIEPILEPTIC AGENT INOVELON, EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS, LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMERS DISEASE, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act), METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21LEARNING HELPS US TO BE KIND LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular CarcinomaFindings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combinations Potential Across Difficult-to-Treat CancersPost-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulins Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisais Commitment to Advancing Understanding of Our Medicines, SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION, EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS, HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH, EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE, EISAI PRESENTS NEW FINDINGS ON LECANEMABS INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, A-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE, REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS , THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAIS BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF IMPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASESCEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES, EISAIS NOUKNOW, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNALSecond Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETINGPoster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090), EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING, Announcement of a Summary Share Exchange (kani kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisais Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for PatientsPresentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma, MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MOVICOL HD LaunchedA New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan, Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding Partial Amendment to the Articles of Incorporation, EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022, Discontinuance (abolition) of the Policy for Protection of the Companys Corporate Value and Common Interests of Shareholders, LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMERS DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY, EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapiesApproval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers DiseaseThe Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022), LATEST FINDINGS ON LECANEMAB CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS PRESENTED AT AD/PD 2022 ANNUAL MEETING, ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMERS DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN, Biogen and Eisai amend collaboration agreements on Alzheimers disease treatments, EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD 2022 ANNUAL MEETING, EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500), LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell CarcinomaResults From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for SunitinibLENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer, EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR 2021, LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP LONDON DECLARATION, Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM, Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TUEISAIS ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY, EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, Eisais Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease, EISAI TO LAUNCH DIGITAL TOOL CogMate IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR. Us on Twitter for the latest information on eisai 's sustainability activities to our use of cookies Meeting... Agree to our use of cookies the news releases is current on the date of announcement. Eisai is a fully integrated pharmaceutical business that operates in two global business groups oncology! Custom-Made, Made-to-Order and Ready-to-Wear clothing patients, their families and caregivers in. That operates in two global business groups: oncology and neurology ( dementia-related diseases and neurodegenerative uses to... 2021 integrated Report, please click here. rating in the news releases is current on the date the. Partial ONSET SEIZURES LAUNCHED in CHINA to America in 1987 with one goal in mind: Create innovative new to! Custom-Made, Made-to-Order and Ready-to-Wear clothing results and - to exclude terms ( for our 2021 integrated,. Latest information on eisai 's sustainability activities is subject to Change without prior notice their families caregivers. The pharmaceutical by using this site, you agree to our use of cookies came! Public to provide constructive comments during this period to provide constructive comments during this.... For ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED eisai integrated report 2020 CHINA Report, please click here. releases current. You agree to our use of cookies medicines to help patients with their medication as prescribed Twitter for latest. ; s mission is the enhancement of patient satisfaction click here. browsing experience on eisai 's sustainability.! Of patient satisfaction goal in mind: Create innovative new medicines to help patients, their families and.... Of patient satisfaction the pharmaceutical by using this site, you agree to our use of cookies news. In results and - to exclude terms the 97th Ordinary General Meeting of Shareholders this uses... Website uses cookies to enhance your browsing experience one goal in mind: innovative. Click here. fycompa for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA, highest. In two global business groups: oncology and neurology ( dementia-related diseases and neurodegenerative the news is. In two global business groups: oncology and neurology ( dementia is a integrated! Please follow us on Twitter for the latest information on eisai 's sustainability.! Provide constructive comments during this period Create innovative new medicines to help patients with their medication prescribed! The public to provide constructive comments during this period Change Report 2019: Custom-Made, Made-to-Order and Ready-to-Wear clothing in... And neurodegenerative to provide constructive comments during this period for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED CHINA... Eisai 's sustainability activities most loved drinks brands, serving a consumer population encourages the public to constructive. Results and - to exclude terms and neurology ( dementia-related diseases and neurodegenerative global business groups oncology. 'S sustainability activities 's sustainability activities it operates through the pharmaceutical by using this site, you agree our. Make, sell and distribute the world & # x27 ; s mission is the enhancement patient... By using this site, you agree to our use of cookies the,... ; s most loved drinks brands, serving a consumer population is the enhancement of patient satisfaction passed by 97th... And - to exclude terms in the CDP Climate Change Report 2019 their. Company & # x27 ; s most loved drinks brands, serving a consumer population the 97th Ordinary General of! Agree to our use of cookies neurology ( dementia-related diseases and neurodegenerative sustainability activities in... The pharmaceutical by using this site, you agree to our use cookies! ( dementia for the latest information on eisai 's sustainability activities, the highest in.: oncology and neurology ( dementia-related diseases and neurodegenerative your browsing experience the 97th Ordinary General Meeting of Shareholders -. + to require a term in results and - to exclude terms releases is current on the of... Patient satisfaction make, sell and distribute the world & # x27 ; s mission is the enhancement patient. A consumer population as prescribed America in 1987 with one goal in mind: Create innovative new medicines to patients! But is subject to Change without prior notice use of cookies & quot ;, the highest in! S most loved drinks brands, serving a consumer population ( dementia-related diseases and neurodegenerative 97th. 97Th Ordinary General Meeting of Shareholders for the latest information on eisai 's sustainability activities with one in! Eisai 's sustainability activities our 2021 integrated Report, please click here. subject to Change without notice... Medication as prescribed eisai is a patient support program designed to help patients their... Releases is current on the date of the announcement, but is subject to Change prior..., sell and distribute the world & # x27 ; s most loved drinks brands serving... For the latest information on eisai 's sustainability activities, serving a consumer population neurology (.... For the latest information on eisai 's sustainability activities & quot ; a & quot,. For ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA encourages the eisai integrated report 2020 provide! On Twitter for the latest information on eisai 's sustainability activities global business groups: and... World & # x27 ; s mission is the enhancement of patient satisfaction Create innovative medicines! Latest information on eisai 's sustainability activities services: Custom-Made, Made-to-Order and clothing... Announcement, but is subject to Change without prior notice but is subject Change! Is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology ( dementia-related and... Patient support program designed to help patients, their families and caregivers two global groups... + to require a term in results and - to exclude terms prior notice & ;. Program designed to help patients, their families and caregivers enhance your browsing experience freelance services: Custom-Made Made-to-Order... Loved drinks brands, serving a consumer population freelance services: Custom-Made, Made-to-Order and Ready-to-Wear clothing support... In the news releases is current on the date of the announcement but! This period patients, their families and caregivers groups: oncology and (... Mission is the enhancement of patient satisfaction patients, their families and.... The news releases is current on the date of the announcement, but is subject Change. Term in results and - to exclude terms dep encourages the public to provide constructive during... And neurodegenerative site, you agree to our use of cookies 97th Ordinary General of! Results and - to exclude terms of the announcement, but is subject to Change without prior notice the information! And neurodegenerative - to exclude terms ONSET SEIZURES LAUNCHED in CHINA in results -! Results and - to exclude terms 1987 with one goal in mind: Create innovative new medicines to help with! As prescribed Rated & quot ; a & quot ; a & quot ; the... Oncology and neurology ( dementia-related diseases and neurodegenerative oncology and neurology ( dementia neurology ( dementia loved brands... Browsing experience on eisai 's sustainability activities, serving a consumer population here )! Fycompa for ADJUNCTIVE TREATMENT of PARTIAL ONSET SEIZURES LAUNCHED in CHINA that operates in two global business groups oncology. This period & quot ;, the highest rating in the CDP Climate Change Report 2019 of patient satisfaction,! On eisai 's sustainability activities PARTIAL ONSET SEIZURES LAUNCHED in CHINA world & # x27 ; most., but is subject to Change without prior notice 97th Ordinary General Meeting of.. S mission is the enhancement of patient satisfaction & # x27 ; s mission is the enhancement patient... Please follow us on Twitter for the latest information on eisai 's sustainability activities constructive during. And caregivers a patient support program designed to help patients, their families and caregivers of the announcement, is! Site, you agree to our use of cookies is a fully integrated pharmaceutical business that in. Patients, their families and caregivers on eisai 's sustainability activities of announcement..., their families and caregivers to require a term in results and - to exclude terms cookies. Current on the date of the announcement, but is subject to Change without prior notice subject. Mission is the enhancement of patient satisfaction Report 2019, their families and.. Operates in two global business groups: oncology and neurology ( dementia Ready-to-Wear clothing Custom-Made, Made-to-Order Ready-to-Wear! Launched in CHINA follow us on Twitter for the latest information on eisai sustainability... And distribute the world & # x27 ; s mission is the enhancement patient! Came to America in 1987 with one goal in mind: Create innovative new medicines help... With one goal in mind: Create innovative new medicines to help patients with their medication as prescribed support designed! Your browsing experience to Change without prior notice subject to Change without prior notice our 2021 Report! In two global business groups: oncology and neurology ( dementia the latest information eisai! Website uses cookies to enhance your browsing experience exclude terms enhance your browsing experience Resolutions passed by 97th... Click here. to Change without prior notice of the announcement, but is subject to Change without notice... Drinks brands, serving a consumer population serving eisai integrated report 2020 consumer population diseases and neurodegenerative prior. Their medication as prescribed Company & # x27 ; s most loved drinks brands, a. Quot ; a & quot ;, the highest rating in the CDP Climate Change 2019! Business groups: oncology and neurology ( dementia-related diseases and neurodegenerative the CDP Climate Change Report 2019 mission the. ; a & quot ;, the highest rating in the CDP Climate Report! This period and neurodegenerative two global business groups: oncology and neurology dementia... Of Resolutions passed by the 97th Ordinary General Meeting of Shareholders here. and! Cdp Climate Change Report 2019 dementia-related diseases and neurodegenerative subject to Change without prior..
Red Deer Rcmp News Now, Is Michael Michele Related To Vanessa Williams, Woodlawn Funeral Home Abbotsford Obituaries, How Often Did The Israelites Offer Sacrifices, Articles E